Alto Neuroscience, Inc. (ANRO)
| Market Cap | 798.04M +1,103.2% |
| Revenue (ttm) | n/a |
| Net Income | -74.31M |
| EPS | -2.45 |
| Shares Out | 35.09M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 558,218 |
| Open | 22.50 |
| Previous Close | 21.79 |
| Day's Range | 21.76 - 23.51 |
| 52-Week Range | 2.15 - 28.44 |
| Beta | 1.25 |
| Analysts | Strong Buy |
| Price Target | 35.13 (+54.49%) |
| Earnings Date | May 13, 2026 |
About ANRO
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company’s product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 pro... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for ANRO stock is "Strong Buy." The 12-month stock price target is $35.13, which is an increase of 54.49% from the latest price.
News
Alto Neuroscience Transcript: 7th Annual HCW Neuro Perspectives Hybrid Conference
The summit highlighted advances in precision psychiatry using EEG biomarkers to guide drug development for neuropsychiatric disorders. Key programs, including ALTO-207 for TRD, are progressing through late-stage trials with major data readouts and regulatory milestones expected by 2027.
Alto Neuroscience highlights publication in Nature Medicine on Prime-Praxol
Alto Neuroscience (ANRO) highlighted the publication in Nature Medicine of Prime-Praxol, an independent, randomized, double-blind, placebo-controlled trial of the dopamine agonist pramipexole in patie...
Alto Neuroscience Highlights Nature Medicine Publication Demonstrating Significant Effects of Pramipexole on Anhedonia
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today highlighted the publication in Nature Medicine of PRIME-PRAXOL, an independent, randomized, d...
Alto Neuroscience Slides: Corporate presentation
Alto Neuroscience has posted slides in relation to its latest quarterly earnings report, which was published on June 15, 2026.
Alto Neuroscience Transcript: Jefferies Global Healthcare Conference 2026
Precision psychiatry pipeline advances with ALTO-207, ALTO-300, and ALTO-100, each targeting major unmet needs in depression and bipolar disorder. Phase II-B and III trials are underway, with rigorous patient selection and strong financial runway through 2029.
Alto Neuroscience appoints Miller to Board of Directors
Alto Neuroscience (ANRO) announced the appointment of Andrew Miller, Ph.D. to its Board of Directors, effective May 27, 2026. Most recently, Miller was the Founder and President of R&D at…
Alto Neuroscience Appoints Karuna Therapeutics Founder Andrew Miller, Ph.D. to Board of Directors
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines...
Alto Neuroscience price target lowered to $33 from $35 at BofA
BofA analyst Tazeen Ahmad lowered the firm’s price target on Alto Neuroscience (ANRO) to $33 from $35 and keeps a Buy rating on the shares. The firm updated its model…
Alto Neuroscience price target lowered to $36 from $38 at Baird
Baird lowered the firm’s price target on Alto Neuroscience (ANRO) to $36 from $38 and keeps an Outperform rating on the shares. The firm updated its model following Q1 results.
Alto Neuroscience CEO Amit Etkin, M.D., Ph.D. Receives Columbia University Transformational Research Award
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neur...
Alto Neuroscience price target raised to $24 from $21 at Wedbush
Wedbush analyst Laura Chico raised the firm’s price target on Alto Neuroscience (ANRO) to $24 from $21 and keeps a Neutral rating on the shares. Most notable in the Q1…
Alto Neuroscience Transcript: Bank of America Global Healthcare Conference 2026
The company is advancing a biomarker-driven pipeline for psychiatric disorders, with ALTO-207 showing strong efficacy and improved tolerability in treatment-resistant depression. Multiple late-stage trials are underway, funded through 2029, with major clinical catalysts expected soon.
Alto Neuroscience reports Q1 EPS (80c) vs (56c) last year
“2026 is off to a strong start across our pipeline, highlighted by the initiation of the Phase 2b trial of ALTO-207 in TRD,” said Amit Etkin, M.D., Ph.D., founder and…
Alto Neuroscience Reports First Quarter 2026 Financial Results and Recent Business Highlights
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines...
Alto Neuroscience Earnings release: Q1 2026
Alto Neuroscience released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
Alto Neuroscience Quarterly report: Q1 2026
Alto Neuroscience has published its Q1 2026 quarterly earnings report on May 13, 2026.
Alto Neuroscience Slides: Corporate presentation
Alto Neuroscience has posted slides in relation to its latest quarterly earnings report, which was published on May 11, 2026.
Alto Neuroscience Announces Participation in Upcoming Investor Conferences
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines...
Alto Neuroscience initiated with a Buy at BofA
BofA analyst Tazeen Ahmad initiated coverage of Alto Neuroscience (ANRO) with a Buy rating and $35 price target The clinical-stage biotech company’s, ALTO-207, is in development for treatment-resistan...
Alto Neuroscience presents Phase 2a data for ALTO-207 in MDD
Alto Neuroscience (ANRO) announced the presentation of data from a randomized, single-blind, placebo-controlled Phase 2a trial of ALTO-207 in patients with Major Depressive Disorder, MDD. The data wer...
Alto Neuroscience Presents Phase 2a Data for ALTO-207 in Major Depressive Disorder at SOBP Annual Meeting
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on precision medicines for neuropsychiatric disorders, t...
Alto Neuroscience participates in a conference call with H. C. Wainwright
Healthcare Analyst Trucchio holds a conference call with CEO Etkin to discuss Alto’s precision psychiatry pipeline on May 5 at 12 pm hosted by H.C. Wainwright.Webcast Link Published first on…
Alto Neuroscience initiates Phase 2b trial of ALTO-207 in TRD
Alto Neuroscience (ANRO) announced the initiation of a Phase 2b randomized, placebo-controlled trial of ALTO-207 in treatment-resistant depression, a program designed to replicate the strongly positiv...
Alto Neuroscience Initiates Phase 2b Trial of ALTO-207 in Treatment-Resistant Depression
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on precision medicines for neuropsychiatric disorders, t...
Alto Neuroscience files to sell 6M shares of common stock for holders
16:03 EDT Alto Neuroscience (ANRO) files to sell 6M shares of common stock for holders